Serendipity Biosciences

Gene-editing technology and genetic medicines are developed for therapeutic uses.
Request Access

About Serendipity Biosciences

Gene-editing technologies and genetic medicines are developed by Serendipity Biosciences within the biotechnology sector. Proprietary gene editing assets are maintained, alongside a toolbox of next-generation editors. Operations focus on expanding therapeutic applications, including reverse transcriptase-based editing and insertion of large DNA regions. Leadership is provided by CEO Devyn Smith, with activities centered on advancing genetic therapies.

  • Sectors
    Healthcare
  • Phone
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Serendipity Biosciences

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Serendipity Biosciences

Serendipity Biosciences has secured backing from 1 investor. Prominent investors backing the company include Arbor Biotechnologies. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Genomic technologies and drug discovery platforms are provided.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Serendipity Biosciences

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Serendipity Biosciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Serendipity Biosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Serendipity Biosciences

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Serendipity Biosciences

Frequently Asked Questions about Serendipity Biosciences

Who is the current CEO of Serendipity Biosciences?

Devyn Smith is the current CEO of Serendipity Biosciences.

What does Serendipity Biosciences do?

Gene-editing technologies and genetic medicines are developed by Serendipity Biosciences within the biotechnology sector. Proprietary gene editing assets are maintained, alongside a toolbox of next-generation editors. Operations focus on expanding therapeutic applications, including reverse transcriptase-based editing and insertion of large DNA regions. Leadership is provided by CEO Devyn Smith, with activities centered on advancing genetic therapies.

Who are Serendipity Biosciences's investors?

Serendipity Biosciences has 1 investor. Key investors include Arbor Biotechnologies.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available